Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Rouhigharabaei, Leila ^a   Ferreiro, Julio Finalet ^a   Tousseyn, Thomas ^b   Van Der Krogt, Jo Anne ^a   Put, Natalie ^a   Haralambieva, Eugenia ^c   Graux, Carlos ^d   Maes, Brigitte ^e   Vicente, Carmen ^a,f   Vandenberghe, Peter ^a   Cools, Jan ^a,f   Wlodarska, Iwona ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^e VIRGA JESSE HOSPITAL   (Belgium)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CHIMERA; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 3; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FOXP1 GENE; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC CORRELATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MALE; MARGINAL ZONE LYMPHOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; WESTERN BLOTTING;

CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 3; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN ISOFORMS; REPRESSOR PROTEINS; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA;

EID: 84897404812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085851     Document Type: Article

References (59)

1. Carlsson P, Mahlapuu M (2002) Forkhead transcription factors: key players in development and metabolism. Dev Biol 250: 1-23.
2. Tuteja G, Kaestner KH (2007) Forkhead transcription factors II. Cell 131: 192.
3. Wang B, Lin D, Li C, Tucker P (2003) Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem 278: 24259-24268. (Pubitemid 37548575)
4. Feng X, Wang H, Takata H, Day TJ, Willen J, et al (2011) Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 12: 544-550.
5. Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting KL, Aznar MA, et al (2013) Downregulation of FOXP1 is required during germinal center B-cell function. Blood 121: 4311-4320.
6. Zhang Y, Li S, Yuan L, Tian Y, Weidenfeld J, et al (2010) Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev 24: 1746-1757.
7. Shi C, Sakuma M, Mooroka T, Liscoe A, Gao H, et al (2008) Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. Blood 112: 4699-4711.
8. Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, et al (2011) An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 147: 132-146.
9. Hu H, Wang B, Borde M, Nardone J, Maika S, et al (2006) Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol 7: 819-826. (Pubitemid 44084088)
10. Kubo H, Shimizu M, Taya Y, Kawamoto T, Michida M, et al (2009) Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry. Genes Cells 14: 407-424.
11. Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, et al (2010) MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 33: 48-59.
12. Shu W, Lu MM, Zhang Y, Tucker PW, Zhou D, et al (2007) Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development 134: 1991-2000. (Pubitemid 46939243)
13. Wang B, Weidenfeld J, Lu MM, Maika S, Kuziel WA, et al (2004) Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131: 4477-4487. (Pubitemid 39409689)
14. Wang Y, Morrisey E (2010) Regulation of cardiomyocyte proliferation by Foxp1. Cell Cycle 9: 4251-4252.
15. Koon HB, Ippolito GC, Banham AH, Tucker PW (2007) FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 11: 955-965. (Pubitemid 47061317)
16. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, et al (2001) The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61: 8820-8829. (Pubitemid 34013896)
17. Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, et al (2013) Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol 231: 130-141.
18. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, et al (2005) Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11: 1065-1072. (Pubitemid 40175755)
19. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS (2004) Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104: 2933-2935. (Pubitemid 39434982)
20. Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A (2010) FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 57: 73-80.
21. Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, et al (2008) The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 22: 1917-1924.
22. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, et al (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105: 13520-13525.
23. Shaffer AL, Rosenwald A, Staudt LM (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2: 920-932. (Pubitemid 37323213)
24. Han SL, Wu XL, Wan L, Zeng QQ, Li JL, et al (2009) FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. Dig Surg 26: 156-162.
25. Jiang W, Li L, Tang Y, Zhang WY, Liu WP, et al (2012) Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. Med Oncol 29: 3352-3359.
26. Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, et al (2006) Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 24: 2490-2497. (Pubitemid 46630625)
27. Zhai L, Zhao Y, Ye S, Huang H, Tian Y, et al (2011) Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. Tumour Biol 32: 913-920.
28. Brown PJ, Ashe SL, Leich E, Burek C, Barrans S, et al (2008) Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 111: 2816-2824.
29. Green MR, Gandhi MK, Courtney MJ, Marlton P, Griffiths L (2009) Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in Follicular Lymphoma. Leuk Res 33: 1699-1702.
30. Courts C, Brunn A, Montesinos-Rongen M, Siemer D, Hans V, et al (2009) Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma. J Neuropathol Exp Neurol 68: 972-976.
31. Fenton JA, Schuuring E, Barrans SL, Banham AH, Rollinson SJ, et al (2006) t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 45: 164-168. (Pubitemid 43191023)
32. Goatly A, Bacon CM, Nakamura S, Ye H, Kim I, et al (2008) FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod Pathol 21: 902-911. (Pubitemid 351896666)
33. Haralambieva E, Adam P, Ventura R, Katzenberger T, Kalla J, et al (2006) Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 20: 1300-1303. (Pubitemid 43905839)
34. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A (2005) T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19: 652-658. (Pubitemid 40521171)
35. Wlodarska I, Veyt E, de Paepe P, Vandenberghe P, Nooijen P, et al (2005) FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 19: 1299-1305. (Pubitemid 41136318)
36. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282. (Pubitemid 38029949)
37. Hu J, Ge H, Newman M, Liu K (2012) OSA: a fast and accurate alignment tool for RNA-Seq. Bioinformatics 28: 1933-1934.
38. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106.
39. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100: 9991-9996. (Pubitemid 37087056)
40. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470: 115-119.
41. Lenz G, Davis RE, Ngo VN, Lam L, George TC, et al (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319: 1676-1679. (Pubitemid 351432507)
42. Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, et al (2011) Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 117: 6227-6236.
43. Hall DC, Johnson-Pais TL, Grubbs B, Bernal R, Leach RJ, et al (2008) Maspin reduces prostate cancer metastasis to bone. Urol Oncol 26: 652-658.
44. Wong KK, Gascoyne DM, Brown PJ, Soilleux EJ, Snell C, et al (2013) Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia In press.
45. Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, et al (2003) MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 101: 4539-4546. (Pubitemid 36857825)
46. Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, et al (2003) T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101: 2335-2339. (Pubitemid 36302078)
47. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, et al (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93: 3601-3609. (Pubitemid 29249804)
48. Motegi M, Yonezumi M, Suzuki H, Suzuki R, Hosokawa Y, et al (2000) API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am J Pathol 156: 807-812. (Pubitemid 30626938)
49. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, et al (2006) The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 108: 3520-3529.
50. Pajer P, Pecenka V, Kralova J, Karafiat V, Prukova D, et al (2006) Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 66: 78-86. (Pubitemid 43166012)
51. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, et al (2010) Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood 115: 3089-3097.
52. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, et al (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758-764. (Pubitemid 46582031)
53. Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Zielvan der Made A, et al (2008) Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68: 7541-7549.
54. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, et al (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44: 47-52.
55. Nunez G, Seto M, Seremetis S, Ferrero D, Grignani F, et al (1989) Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 86: 4589-4593. (Pubitemid 19164596)
56. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442.
57. Taniguchi IE, Chang KH, Nayak R, Olsson HA, Ficker AM, et al (2013) Klf5 controls bone marrow homing of stem cells and progenitors through Rab5-mediated beta1/beta2-integrin trafficking. Nat Commun 4: 1660.
58. Dong JT, Chen C (2009) Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 66: 2691-2706.
59. Mao X, Miao S, He H, Miao S, Pei R, et al (2013) Kruppel-like factor 5: a novel biomarker for lymph node metastasis and recurrence in supraglottic squamous cell laryngeal carcinoma. Tumour Biol In press.